Use of Attention Deficit Hyperactivity Disorder Medication Among Danish Children and Adolescents From 2010 to 2023
Open Access
- 21 April 2026
- journal article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 154 (3) , 203-211
Abstract
Introduction: Pharmacological treatment is an important component in the multimodal management of attention deficit hyperactivity disorder (ADHD), but contemporary trends in ADHD medication use among boys and girls in Denmark have not been fully characterized. This study aimed to provide an updated and detailed description of ADHD medication use among Danish children and adolescents during 2010–2023. Methods: We analyzed filled prescriptions for ADHD medication in youths aged 5–17 years in Denmark (2010–2023), calculating incidence rates, prevalence proportions, male/female ratios, treatment persistence, age at initiation, and prescriber setting. Analyses were stratified by sex and age. Results: The incidence rates of ADHD medication use followed a u‐shaped pattern for boys, declining from 0.59 per 100 person‐years in 2010 to 0.34 in 2014, before rising to 1.0 in 2023. Among girls, incidence rates increased continuously from 0.20 per 100 person‐years in 2010 to 0.67 per 100 person‐years in 2023. Prevalence proportions were stable until 2018, where an increase was observed for both sexes, reaching 3.4% for boys and 1.8% for girls in 2023. The male/female incidence and prevalence ratios decreased consistently from 2010 to 2023. ADHD medication was initiated at a median age of 13 years for girls and 11 years for boys. The share of index prescriptions from child and adolescent psychiatry increased, reaching 87% in 2023. Most 5–9‐year‐olds (65%) and almost half of 10–13‐year‐olds (45%) were covered by an ADHD medication prescription 5 years after treatment initiation, as opposed to 29% of 14–17‐year‐olds. Conclusion: ADHD medication use in Denmark increased from 2010 to 2023, particularly among girls, where the prevalence tripled compared to a 1.5‐fold increase in boys. This likely reflects greater awareness of ADHD in girls, although their 2‐year treatment delay compared to boys warrants clinical attention.Keywords
This publication has 36 references indexed in Scilit:
- Psychotropic drug use among children and adolescents in the Nordic countries: a systematic reviewEuropean Child & Adolescent Psychiatry, 2024
- Medication adherence and persistence in children and adolescents with attention deficit hyperactivity disorder (ADHD): a systematic review and qualitative updateEuropean Child & Adolescent Psychiatry, 2024
- Psychotropic Medication Use and Psychiatric Disorders During the COVID-19 Pandemic Among Danish Children, Adolescents, and Young AdultsJAMA Psychiatry, 2023
- Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010–2020European Child & Adolescent Psychiatry, 2022
- Exploring Comorbidity Within Mental Disorders Among a Danish National PopulationJAMA Psychiatry, 2019
- Using the “proportion of patients covered” and the Kaplan‐Meier survival analysis to describe treatment persistencePharmacoepidemiology and Drug Safety, 2018
- Primary non-adherence in general practice: a Danish register studyEuropean Journal of Clinical Pharmacology, 2014
- Enhancing ADHD Medication Adherence: Challenges and OpportunitiesCurrent Psychiatry Reports, 2013
- The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspectiveEuropean Journal of Clinical Pharmacology, 2012
- The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspectiveEuropean Journal of Clinical Pharmacology, 2012